You are reading one round. Fundz also knows which of your own LinkedIn connections can open this account.See it live →
Shennon Biotechnologies raises $12M in financing for its precision immunotherapy pipeline and appoints Cyril Konto, M.D., as Chief Executive Officer.
PRIVATESep 14, 2026•about 1 hour ago
Amount Raised
$12 Million
Round Type
Venture - Series Unknown
San FranciscoBiotechnology
Description
Shennon Biotechnologies has successfully raised $12 million in financing. The funds will be utilized to support the development of its precision immunotherapy pipeline. Additionally, Cyril Konto, M.D., has been appointed as the new Chief Executive Officer. This move is expected to bolster the company's leadership as it progresses in the biotechnology field.
Company Information
Company
Shennon Biotechnologies
Location
953 INDIANA STREET
San Francisco, California, United States
About
ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8.
Don't miss Shennon Biotechnologies's next move
Get an email the moment Shennon Biotechnologies raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Shennon Biotechnologies's next move
San FranciscoBiotechnology